261635-79-4 Usage
Uses
Used in Pharmaceutical Industry:
METHYL 6-CHLORO-4-(TRIFLUOROMETHYL)NICOTINATE is used as an intermediate in the synthesis of active pharmaceutical ingredients for various therapeutic applications. Its role in the development of new chemical entities in medicinal chemistry is crucial, as it can contribute to the creation of novel drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL 6-CHLORO-4-(TRIFLUOROMETHYL)NICOTINATE is employed as an intermediate in the production of crop protection products. Its insecticidal and fungicidal properties make it a valuable component in the formulation of pesticides and fungicides, which are essential for maintaining crop health and productivity.
Used in Medicinal Chemistry Research:
METHYL 6-CHLORO-4-(TRIFLUOROMETHYL)NICOTINATE is utilized as a building block in medicinal chemistry research for the development of new chemical entities. Its unique structure and biological activities provide a foundation for the design and synthesis of innovative compounds with potential applications in various therapeutic areas.
Check Digit Verification of cas no
The CAS Registry Mumber 261635-79-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,1,6,3 and 5 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 261635-79:
(8*2)+(7*6)+(6*1)+(5*6)+(4*3)+(3*5)+(2*7)+(1*9)=144
144 % 10 = 4
So 261635-79-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H5ClF3NO2/c1-15-7(14)4-3-13-6(9)2-5(4)8(10,11)12/h2-3H,1H3
261635-79-4Relevant academic research and scientific papers
INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
-
, (2019/04/10)
The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
-
, (2017/09/15)
The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
-
Paragraph 00320; 00326-00327, (2017/09/15)
The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
